Patients who have chronic hepatitis C with advanced fibrosis have twice the risk of developing liver cancer if they also have diabetes. These findings are published in the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (www.interscience.wiley.com).
Recent studies have suggested that diabetes increases one’s risk for hepatocellular carcinoma (HCC), also known as liver cancer, possibly because diabetes often occurs as part of the metabolic syndrome, which increases the risk of non-alcoholic steatohepatitis (NASH), which can lead to liver cancer. Chronic hepatitis C also increases the risk of liver cancer, so patients who have both diabetes and hepatitis C have two pathways through which HCC might develop.
Researchers led by Bart Veldt and Harry Janssen of the Erasmus MC University Medical Center in the Netherlands, aimed to quantify the liver cancer risk of patients who have both diabetes mellitus and advanced hepatitis C. They used data from five large hepatology units in Europe and Canada and included 541 consecutive patients between 1990 and 2003 who had chronic hepatitis C and advanced liver fibrosis or cirrhosis as shown by liver biopsy. For each patient, they gathered demographic, clinical, biochemical and virological data, along with fibrosis assessment and details of hepatitis C treatment.
Eighty-five of the 541 patients included in the study had diabetes. Patients with more severe fibrosis were more likely to be diabetic. “The prevalence of diabetes mellitus was 10.5 percent for patients with Ishak fibrosis score 4, 12.5 percent for Ishak-score 5 and 19.1 percent for Ishak-score 6,” the authors report.
During the median follow-up time of four years, 11 patients (13 percent) with diabetes vs. 27 patients (5.9 percent) without diabetes developed hepatocellular carcinoma. The 5-year occurrence was 11.4 percent and 5.0 percent, respectively. Male gender and older age were significantly associated with elevated HCC risk. “In addition, there was a strong trend towards a higher incidence of HCC among patients with diabetes mellitus,” the authors report. Multivariate Cox regression analysis of patients with Ishak 6 cirrhosis showed that diabetes was independently associated with the development of HCC.
Interestingly, among patients with diabetes, there was a trend towards higher risk of HCC as fasting glucose levels increased. The authors hypothesize that resulting hyperinsulinemia might help explain the increased risk of HCC among diabetic patients.
Whatever the mechanism, the risk is clear. “For patients with chronic hepatitis C and advanced cirrhosis, diabetes mellitus increases the risk of developing HCC,” the authors conclude.
Article: “Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.” Veldt, Bart; Chen, Wendong; Heathcote, E. Jenny; Wedemeyer, Heiner; Reichen, Jurg; Hofmann, Wolf; de Knegt, Rob; Zeuzem, Stefan; Manns, Michael; Hansen, Bettina; Schalm, Solko; Janssen, Harry. Hepatology ; June 2008; DOI: 10.1002/hep.22251.
Note to members of the press only:
For a copy of this article, please contact Sean Wagner at 781-388-8550 or by email at medicalnews@bos.blackwellpublishing.com.
About Wiley InterScience
Introduced in 1997 and launched commercially in January 1999, Wiley InterScience (www.interscience.wiley.com ) is a leading international resource for quality content promoting discovery across the spectrum of scientific, technical, medical and professional endeavors. In nearly a decade, Wiley InterScience has built its reputation by regularly adding new content and functionality; offering sophisticated search and navigation capabilities; and providing robust online manuscript submission and management tools.
Today, Wiley InterScience features must-have content from more than 2,500 journals, books, reference works, databases, laboratory manuals and the Cochrane Library, which is the world’s best-known resource for evidence-based medicine. More than half of Wiley’s journals on Wiley InterScience are digitized back to Volume 1, Issue 1 as part of the development of the journal backfile initiative. Wiley InterScience is one of the largest archives of its kind, with content dating back to 1799 and over 2 million articles of scientific and scholarly research.
About Wiley
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for 200 years, helping people around the world meet their needs and fulfill their aspirations. Our core businesses include scientific, technical, medical, and scholarly journals, encyclopedias, books, and online products and services; professional/trade books, subscription products, training materials, and online products and services; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company’s Web site can be accessed at www.wiley.com . The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.